ABT Stock: Evercore Trims Price Target but Holds Buy as Abbott Trades Near 52-Week Low

April 7, 2026

By TrendSpider Editor

ABT Stock: Evercore Trims Price Target but Holds Buy as Abbott Trades Near 52-Week Low

Evercore Partners analyst Vijay Kumar reaffirmed a Buy rating on Abbott Laboratories while cutting the price target from $138 to $134, a signal of tempered optimism as the stock hovers just above its 52-week low. Abbott shares edged up a nominal 0.02% to $102.32 on Tuesday, a price that sits uncomfortably close to the 52-week trough of $100.875 and far below the 52-week high of $139.05. The gap between the current price and the revised $134 target implies meaningful upside, but the proximity to the yearly floor raises questions about near-term momentum.

Key Drivers of the ABT Stock Move

Main Catalyst: Evercore Partners, through analyst Vijay Kumar, confirmed a Buy rating on Abbott Laboratories while lowering its price target by $4 to $134 from a prior $138. The action is a confirmation rather than an upgrade or downgrade, suggesting the firm remains constructive but is adjusting its valuation assumptions downward.
Bull Case: Even after the trim, the $134 average price target represents approximately 31% upside from the current price of $102.32. Evercore's maintained Buy rating signals that at least one major institution views the current price level near the 52-week low of $100.875 as an opportunity rather than a warning sign.
Bear Case: The reduction in price target from $138 to $134 reflects a more cautious outlook, and the stock's failure to gain meaningful traction despite a Buy reaffirmation is notable. A 0.02% price move on an analyst action day suggests limited buying conviction from the broader market, and the stock remains 26% below its 52-week high of $139.05.

The forward setup for Abbott is shaped by the tension between a still-supportive analyst community and a stock that has spent recent weeks grinding near its yearly floor. With the price target cut arriving alongside a rating hold rather than an upgrade, investors will likely look to Abbott's next earnings report and any commentary on its diagnostics and medical device segments for a clearer fundamental catalyst. The stock's current positioning near $102 creates a fairly defined risk level just below $100.875, making the 52-week low a closely watched technical line in the weeks ahead.

ABT Analyst Ratings and Price Targets

Evercore Partners analyst Vijay Kumar confirmed a Buy rating on Abbott Laboratories on Tuesday, April 7, 2026, while reducing the price target to $134 from a prior $138. The action reflects a modest downward revision of $4 in the firm's valuation without a change in overall directional conviction. The consensus average price target across coverage stands at $134, aligning precisely with Evercore's revised figure. There were no upgrades or downgrades recorded in this action cycle, with a total of one analyst action reported.

ABT Seasonality

April has historically been an active month for Abbott given the proximity to first-quarter earnings season, which often serves as a reset point for analyst price targets and institutional positioning. A reaffirmed Buy rating entering this period may reflect an analyst getting ahead of upcoming results rather than reacting to any single near-term catalyst.

ABT Relative Performance

Abbott's 0.02% gain on Tuesday is essentially flat, underperforming any broad market session that sees meaningful movement in either direction. With the stock trading at $102.32 against a 52-week high of $139.05, Abbott has lagged significantly on a trailing twelve-month basis relative to where it was at its peak, and the narrow trading range near the yearly low suggests the stock has yet to attract the kind of institutional buying that would signal a durable recovery relative to the broader healthcare and medical device peer group.